Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “United Kingdom”

Tracheostomy Practice in Adult Intensive Care UnitsNot Yet Recruiting
NCT07769021N/AUpdated Aug 17, 2026
Sponsor: Royal College of Surgeons, Ireland
Tracheostomy Patients · Tracheostomy Decannulation · Intensive Care (ICU)
United States, Brazil, Canada, India, Ireland +3 more
5G-EMERALD: Amivantamab in Malignant Brain TumoursActive Not Recruiting
NCT06632236Phase 1Updated Aug 17, 2026
Sponsor: Institute of Cancer Research, United Kingdom
Malignant Primary Gliomas · Glioblastoma Multiform (Grade IV Astrocytoma) · Diffuse Hemispheric Glioma, H3 G34-Mutant · Glioblastoma Multiforme (GBM)
United Kingdom
A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, Explore the Effect of Food After Multiple Doses of Selected Prototypes, and Evaluate Alternative Formulations of KarX and KarXT Following Single and Multiple Ascending DosesRecruiting
NCT07063342Phase 1Updated Aug 17, 2026
Sponsor: Bristol-Myers Squibb
Healthy Volunteers
United Kingdom
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.Recruiting
NCT07440290Phase 2, Phase 3Updated Aug 17, 2026
Sponsor: Cancer Research UK
Haematological Malignancy · Malignant Neoplasm · Lymphoproliferative Disorders · Neoplasms by Histologic Type
United Kingdom
A Prospective Study of Pediatric Participants up to 16 Years of Age With Methylmalonic Acidemia (MMA) Due to Mutations in the MMUT GeneRecruiting
NCT07432880N/AUpdated Aug 17, 2026
Sponsor: Genespire Srl
Methylmalonic Acidemia (MMA)
United States, Italy, Spain, United Kingdom
The Val-CARD TrialTerminated
NCT03825250Phase 1, Phase 2Updated Aug 17, 2026
Sponsor: University of Leicester
Cardiac Valve Disease · Coronary Artery Disease · Organ Failure, Multiple
United Kingdom
Arterial Stiffness in Children and Young People With Hypertension and Chronic Kidney DiseaseRecruiting
NCT07768865N/AUpdated Aug 17, 2026
Sponsor: King's College London
Chronic Kidney Disease · Hypertension
United Kingdom
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 AsthmaRecruiting
NCT07456033Phase 3Updated Aug 17, 2026
Sponsor: GlaxoSmithKline
Asthma
United States, United Kingdom
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic AsthmaRecruiting
NCT07323654Phase 2Updated Aug 17, 2026
Sponsor: Kymera Therapeutics, Inc.
Eosinophilic Asthma
United States, Argentina, Germany, Poland, Romania +5 more
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous DiseaseRecruiting
NCT06605378N/AUpdated Aug 17, 2026
Sponsor: Ensoma
Chronic Granulomatous Disease (CGD)
United States, United Kingdom
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal CancerRecruiting
NCT07221357Phase 2, Phase 3Updated Aug 17, 2026
Sponsor: Bristol-Myers Squibb
Untreated, Unresectable, or Metastatic Colorectal Cancer
United States, Argentina, Australia, Austria, Belgium +21 more
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical PracticeRecruiting
NCT07284121N/AUpdated Aug 17, 2026
Sponsor: Hoffmann-La Roche
Lung Cancer, Hepatocellular Carcinoma
Austria, Belgium, Bulgaria, Italy, Poland +3 more
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)Active Not Recruiting
NCT04862663Phase 3Updated Aug 17, 2026
Sponsor: AstraZeneca
Locally Advanced (Inoperable) or Metastatic Breast Cancer
United States, Argentina, Australia, Belgium, Brazil +18 more
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Recruiting
NCT05254743Phase 3Updated Aug 17, 2026
Sponsor: Loxo Oncology, Inc.
Chronic Lymphocytic Leukemia · Leukemia, Lymphocytic · Leukemia, B-cell · Small Lymphocytic Lymphoma
United States, Argentina, Australia, Austria, Belgium +18 more
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe AsthmaRecruiting
NCT06023589Phase 3Updated Aug 17, 2026
Sponsor: AstraZeneca
Asthma
United States, Argentina, Brazil, Canada, China +17 more
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)Recruiting
NCT07144280Phase 3Updated Aug 17, 2026
Sponsor: Pfizer
Non-small Cell Carcinoma · Non-Small Cell Lung Cancer Metastatic · Non-Small Cell Lung Carcinoma
United States, Argentina, Australia, Belgium, Brazil +24 more
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerRecruiting
NCT07085767Phase 3Updated Aug 17, 2026
Sponsor: Olema Pharmaceuticals, Inc.
Breast Cancer · Locally Advanced Breast Cancer · Metastatic Breast Cancer · ER Positive Breast Cancer
United States, Australia, Austria, Belgium, Canada +18 more
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)Active Not Recruiting
NCT04546009Phase 3Updated Aug 17, 2026
Sponsor: Hoffmann-La Roche
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
United States, Argentina, Australia, Austria, Belgium +25 more
Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)Recruiting
NCT07062588Phase 2Updated Aug 17, 2026
Sponsor: Angitia Incorporated Limited
Osteogenesis Imperfecta (OI)
United States, Argentina, Australia, Canada, Denmark +3 more
OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi SyndromeTerminated
NCT06420297Phase 3Updated Aug 17, 2026
Sponsor: ACADIA Pharmaceuticals Inc.
Hyperphagia in Prader-Willi Syndrome
United States, Canada, France, Germany, Spain +1 more
Study to Investigate the Effect of Changes in Dentinal Hypersensitivity on Oral Health ParametersCompleted
NCT07768969NAUpdated Aug 17, 2026
Sponsor: HALEON
Dentine Hypersensitivity
United Kingdom
The BCI 602 BONEBRIDGE Post-Market Clinical Follow-up StudyCompleted
NCT04427033N/AUpdated Aug 17, 2026
Sponsor: MED-EL Elektromedizinische Geräte GesmbH
Hearing Loss · Hearing Loss, Conductive · Hearing Loss, Mixed · Hearing Loss, Unilateral
Austria, Germany, United Kingdom
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid TumoursActive Not Recruiting
NCT00750841Phase 1Updated Aug 17, 2026
Sponsor: AstraZeneca
Solid Tumors
Canada, United Kingdom
Implementation of Networked Continuous Glucose Monitoring With Telemetry Within the Intensive Care Unit (ICU-TeleCGM)Not Yet Recruiting
NCT07769138N/AUpdated Aug 17, 2026
Sponsor: Imperial College Healthcare NHS Trust
Type 1 Diabetes · Type 2 Diabetes Treated With Insulin · Hyperglycemia · Intensive Care (ICU)
United Kingdom
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated MeningiomasTerminated
NCT05130866Phase 2, Phase 3Updated Aug 17, 2026
Sponsor: Recursion Pharmaceuticals Inc.
Neurofibromatosis Type 2
United States, United Kingdom

Previous page Next page